PainChek Expands into North America with Large-Scale Aged Care Agreement.
PainChek Limited (ASX: PCK) has secured a major commercial agreement with Sabra Health Care REIT, supporting its entry and expansion across the North American aged care market. The partnership enables deployment of PainChek’s AI-based pain assessment solution across up to 20,000 beds within Sabra’s network of senior living and care facilities. By funding the solution at the asset-owner level, the agreement reduces barriers for operators and encourages faster adoption.
The commercial model includes annual pricing between US$55 and US$75 per bed, depending on contract duration and collaboration terms. Sabra will actively introduce the platform to its portfolio of operators, improving scalability and accelerating rollout. This agreement represents a strategic milestone, providing a replicable framework for expansion through similar partnerships with institutional healthcare property owners, while strengthening the company’s growth strategy following its regulatory clearance in the United States.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
PainChek Expands into North America with Large-Scale Aged Care Agreement.
PainChek Limited (ASX: PCK) has secured a major commercial agreement with Sabra Health Care REIT, supporting its entry and expansion across the North American aged care market. The partnership enables deployment of PainChek’s AI-based pain assessment solution across up to 20,000 beds within Sabra’s network of senior living and care facilities. By funding the solution at the asset-owner level, the agreement reduces barriers for operators and encourages faster adoption.
The commercial model includes annual pricing between US$55 and US$75 per bed, depending on contract duration and collaboration terms. Sabra will actively introduce the platform to its portfolio of operators, improving scalability and accelerating rollout. This agreement represents a strategic milestone, providing a replicable framework for expansion through similar partnerships with institutional healthcare property owners, while strengthening the company’s growth strategy following its regulatory clearance in the United States.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au